Clinical trials: Digestive System Cancer
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Oesophageal Cancer
A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
This open-label, one-center, noncomparative, two-stages phase 1B trial assessed the tyrosine kinase inhibitor donafenib tosylate tablets(400 mg/d,200mg bid) in patients with advanced, inoperable oesophageal cancer progressing…
- Trial name
- NCT02489201
- Testing
- donafenib tosilate tablets
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Esophageal Neoplasms
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
The goal of this observational study is to test the clinical efficacy of "KCNA3 and OTOP2 gene methylation combined detection kit (fluorescence PCR method)"in esophageal cancer and high-grade esophageal neoplasia auxiliary…
- Trial name
- NCT05680077
- Testing
- KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
- Where
- China
- Volunteers
- 1,116 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Inflammatory Bowel Disease, Colorectal Neoplasms
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
The primary objective of this study is to gather stool samples from subjects with inflammatory bowel disease (IBD) to be added to a test set of stool samples that will be utilized to help select molecular markers and determine…
- Conditions
- Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases
- Trial name
- NCT02503696
- Testing
- Stool Collection Kit
- Where
- 29 sites in United States, Canada
- Volunteers
- 697 people
- Sponsor
- Exact Sciences Corporation
Colorectal Cancer, Head and Neck Cancer
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
- Trial name
- NCT00908024
- Testing
- BMS-754807, cetuximab (Erbitux®)
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
GI Cancer
Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery
Evaluation of the impact of peri- and post-operative parenteral nutrition enriched with n-3 PUFA on post-operative inflammatory processes.
- Trial name
- NCT00798447
- Testing
- MLF 541, Lipofundin MCT
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- B. Braun Melsungen AG
Hepatocellular Carcinoma
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
- Trial name
- ATHENA (NCT06084884)
- Testing
- AZD5851
- Where
- 19 sites in United States, Japan and 1 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
European Physician Survey of EGFR Inhibitor Prescribing Patterns
To ensure the appropriate administration of Vectibix for the treatment of mCRC with wild-type KRAS in real-world practice, it is important to understand the awareness of practicing oncologists regarding the correct indication and…
- Trial name
- NCT01652833
- Testing
- Physician Survey
- Volunteers
- 453 people
- Sponsor
- Amgen
Esophagitis, Pneumonitis
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small…
- Conditions
- Esophagitis, Pneumonitis, Non-Small Cell Lung Carcinoma
- Trial name
- NCT00081315
- Testing
- Amifostine
- Where
- 24 sites in United States
- Volunteers
- 130 people
- Sponsor
- MedImmune LLC
Metastatic Pancreatic Cancer
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer.
- Trial name
- PGPC1 (NCT01461915)
- Testing
- Nab paclitaxel, Gemcitabine, Dociparstat
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Gastrointestinal Stromal Tumors
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
- Trial name
- NCT01689376
- Testing
- Regorafenib (BAY73-4506)
- Sponsor
- Bayer
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
- Trial name
- TREMENDOUS-2 (NCT07081633)
- Testing
- Durvalumab, Tremelimumab, Lenvatinib
- Where
- 23 sites in China, Hong Kong
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Hepatocellular Carcinoma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
- Trial name
- NCT03971747
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai AbelZeta Ltd.
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections.
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Trial name
- NCT06848348
- Testing
- Halneuron, Halneuron (Open Label Extension)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dogwood Therapeutics Inc.
HER2-positive Breast Cancer, Cervical Cancer
Tucatinib Continuation Study
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment.
- Conditions
- HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer
- Trial name
- NCT07768358
- Testing
- tucatinib
- Volunteers
- 175 people
- Sponsor
- Pfizer
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.